DE69419623D1 - Peptidinhibitoren der urokinaserezeptor-aktivität - Google Patents

Peptidinhibitoren der urokinaserezeptor-aktivität

Info

Publication number
DE69419623D1
DE69419623D1 DE69419623T DE69419623T DE69419623D1 DE 69419623 D1 DE69419623 D1 DE 69419623D1 DE 69419623 T DE69419623 T DE 69419623T DE 69419623 T DE69419623 T DE 69419623T DE 69419623 D1 DE69419623 D1 DE 69419623D1
Authority
DE
Germany
Prior art keywords
urokinas
receptor activity
peptide inhibitors
active
aewsfynlihilpepqtif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69419623T
Other languages
English (en)
Other versions
DE69419623T2 (de
Inventor
Steven Rosenberg
Michael Doyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DE69419623D1 publication Critical patent/DE69419623D1/de
Publication of DE69419623T2 publication Critical patent/DE69419623T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
DE69419623T 1993-05-28 1994-05-19 Peptidinhibitoren der urokinaserezeptor-aktivität Expired - Fee Related DE69419623T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6151493A 1993-05-28 1993-05-28
PCT/US1994/005684 WO1994028014A2 (en) 1993-05-28 1994-05-19 Peptide inhibitors of urokinase receptor activity

Publications (2)

Publication Number Publication Date
DE69419623D1 true DE69419623D1 (de) 1999-08-26
DE69419623T2 DE69419623T2 (de) 1999-12-02

Family

ID=22036265

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69419623T Expired - Fee Related DE69419623T2 (de) 1993-05-28 1994-05-19 Peptidinhibitoren der urokinaserezeptor-aktivität

Country Status (12)

Country Link
US (2) US5656726A (de)
EP (1) EP0745092B1 (de)
JP (2) JPH08510742A (de)
KR (1) KR960702846A (de)
AT (1) ATE182336T1 (de)
AU (1) AU682877B2 (de)
CA (1) CA2163741A1 (de)
DE (1) DE69419623T2 (de)
FI (1) FI955720A (de)
NO (1) NO954722L (de)
NZ (1) NZ267291A (de)
WO (1) WO1994028014A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519120A (en) * 1989-04-07 1996-05-21 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor antibodies
WO1994028145A2 (en) 1993-06-01 1994-12-08 Chiron Corporation Expression of urokinase plasminogen activator inhibitors
US6248715B1 (en) 1993-06-01 2001-06-19 Chiron Corporation Method of treating a urokinase-type plasminogen activator-mediated disorder
AU6505996A (en) * 1995-07-31 1997-02-26 Chiron Corporation Peptide analog inhibitors of urokinase receptor activity
US6030940A (en) * 1995-07-31 2000-02-29 Chiron Corporation Peptide analog inhibitors of urokinase receptor activity
EP0795333A3 (de) * 1996-03-15 2002-05-02 Senju Pharmaceutical Co., Ltd. TGF-beta regulierender Stoff zur Behandlung der Myopia oder Hyperopia
US20040204348A1 (en) * 1996-11-12 2004-10-14 The Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US6277818B1 (en) * 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
DK0970106T3 (da) * 1997-03-20 2005-01-10 San Raffaele Centro Fond uPAR-imiterende peptider
US6794358B1 (en) * 1997-03-28 2004-09-21 Brigham And Women's Hospital Peptide ligands of the urokinase receptor
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
EP1142570A4 (de) 1998-10-02 2003-01-15 Santen Pharmaceutical Co Ltd Angiogenese inhibitoren
GB0002366D0 (en) * 2000-02-03 2000-03-22 Astrazeneca Uk Ltd Diagnostic method
US7566765B2 (en) * 2000-03-06 2009-07-28 Rigel Pharmaceuticals, Inc. Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
US20040052840A1 (en) * 2000-06-20 2004-03-18 Shunichiro Kubota Preparations for oligonucleotide transfer
US6649597B1 (en) * 2000-06-22 2003-11-18 The University Of Iowa Research Foundation Targeting vector to the urokinase plasminogen activator receptor
JP4081436B2 (ja) * 2001-06-20 2008-04-23 大日本住友製薬株式会社 核酸導入を促進させる方法
US6908899B2 (en) * 2001-08-17 2005-06-21 U.S. Dept. Of Veterans Affairs Pro-inflammatory fibrinopeptide
CA2468192A1 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
WO2003051347A1 (en) * 2001-12-19 2003-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of urokinase receptor antagonists to modulate ischemiareperfusion injury
WO2005061717A1 (ja) * 2003-12-19 2005-07-07 Dainippon Sumitomo Pharma Co., Ltd. 新規な核酸導入法
US20090062184A1 (en) * 2005-03-24 2009-03-05 Dainippon Sumitomo Pharma Co., Ltd. Fine particulate preparation comprising complex of nucleic acid molecule and collagen
TW200813091A (en) * 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
CA3036854A1 (en) 2016-09-15 2018-03-22 Labcyte Inc. High-efficiency transfection of biological cells using sonoporation
CN111225684A (zh) 2017-10-12 2020-06-02 Sutrovax公司 牙周炎疫苗和相关组合物及使用方法
AU2018374058A1 (en) 2017-11-22 2020-06-18 Dh Technologies Development Pte. Ltd. System and method for the acoustic loading of an analytical instrument using a continuous flow sampling probe
JP2021515596A (ja) 2018-03-03 2021-06-24 ラブサイト インコーポレイテッド 音響液滴射出を使用して試料から標的部分を抽出するためのシステムおよび方法
MA55528A (fr) 2019-04-02 2022-02-09 Vaxcyte Inc Synthèse acellulaire optimisée d'antigène b de plasmide d'invasion, compositions associées et procédés d'utilisation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631270A (en) * 1978-11-20 1986-12-23 Research Corporation Therapeutically useful pseudopeptides, compositions containing the same and methods of preparation and use
US5519120A (en) * 1989-04-07 1996-05-21 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor antibodies
DK182289D0 (da) * 1989-04-14 1989-04-14 Francesco Blasi Modifikation af proteiner
US5039791A (en) * 1989-11-06 1991-08-13 Monsanto Company Peptide fragments of tissue plasminogen activator
GB2246779B (en) * 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
CA2123874A1 (en) * 1991-11-18 1993-05-27 Ikuko F. Mizukami Methods for detecting and isolating upa-r and inhibiting the binding of upa to upa-r
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors

Also Published As

Publication number Publication date
JPH08510742A (ja) 1996-11-12
WO1994028014A2 (en) 1994-12-08
AU682877B2 (en) 1997-10-23
FI955720A0 (fi) 1995-11-27
CA2163741A1 (en) 1994-12-08
ATE182336T1 (de) 1999-08-15
EP0745092B1 (de) 1999-07-21
AU6954294A (en) 1994-12-20
US5679782A (en) 1997-10-21
JPH11240897A (ja) 1999-09-07
DE69419623T2 (de) 1999-12-02
NO954722D0 (no) 1995-11-22
KR960702846A (ko) 1996-05-23
WO1994028014A3 (en) 1995-01-26
EP0745092A1 (de) 1996-12-04
US5656726A (en) 1997-08-12
NZ267291A (en) 1997-09-22
NO954722L (no) 1995-11-22
FI955720A (fi) 1995-11-27

Similar Documents

Publication Publication Date Title
DE69419623D1 (de) Peptidinhibitoren der urokinaserezeptor-aktivität
FI953378A (fi) Sytokiiniä pidättävät aineet
DE69620161D1 (de) Thrombininhibitoren
DE69528528T2 (de) Thrombin-inhibitoren
DE69825048D1 (de) Analoga von duocarmycin and cc-1065
DE122008000021I1 (de) Sulfonamidderivate als Wirkstoff-Vorläufer von Inhibitoren der Aspartyl-Protease
ATE184022T1 (de) Neuropeptide y antagoniste
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DE69333639D1 (en) Trypsininhibitoren
SE9300012D0 (sv) New peptides
FR2694296B1 (fr) Peptides inhibant l'activité des protéines ras, préparation et utilisation.
DE69917230D1 (de) Kombinationspräparat, das selektive nmda nr2b-antagonisten und cox-2 inhibitoren enthält
DE69432608D1 (de) Expression von inhibitoren vom plasminogenaktivator vom urokinasetyp
DK0556322T3 (da) Aminosulfonylurinstof-ACAT-inhibitorer
NO980296D0 (no) Forbedrede terapeutiske midler
ATE28188T1 (de) Antikonvulsive mittel.
ATE57526T1 (de) P-acylaminobenzamide.
ES2103482T3 (es) Antigeno de linfocitos t citotoxicos utilizado como inhibidor de la cisteina proteasa.
FI913645A0 (fi) Transdermalt system med vilket farmakologiskt aktiva foereningar appliseras i effekt-kontrollerade faorhaollanden.
ATE238346T1 (de) Rho-conotoxin peptide mit selektiver antagonistischer aktivität auf den alpha-1- adrenozeptor
ITBO930092V0 (it) perfezionamento ad un elettrodo ad ancoraggio attivo per elettroca- teteri.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee